GW-405,833: Difference between revisions

{{Drugbox| verifiedrevid = 405758960

|

|IUPAC_name = 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-1H-indole

| CAS_number= 180002-83-9

| ATC_prefix=

| ATC_suffix=

| PubChem= 9911463

| DrugBank=

| molecular_weight = 447.353 g/mol

| smiles = C4COCCN4CCc1c(C)n(c(ccc3OC)c1c3)C(=O)c2cccc(Cl)c2Cl

| bioavailability=

| metabolism =

| elimination_half-life=

| excretion =

| pregnancy_category =

| legal_status =

| routes_of_administration=

'''GW-405,833''' ('''L-768,242''') is a drug which acts as a potent and selective [[partial agonist]] for the [[cannabinoid receptor]] subtype [[Cannabinoid receptor type 2|CB₂]], with an [[EC50|EC₅₀]] of 0.65nM and selectivity of around 1200x for CB₂ over [[Cannabinoid receptor type 1|CB₁]] receptors.<ref>Huffman JW. The search for selective ligands for the CB2 receptor. ''Current Pharmaceutical Design''. 2000 Sep;6(13):1323-37. {{DOI|10.2174/1381612003399347}} PMID 10903395</ref><ref>Marriott KS, Huffman JW. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. ''Current Topics in Medicinal Chemistry''. 2008;8(3):187-204. {{DOI|10.2174/156802608783498014}} PMID 18289088</ref> Animal studies have shown it to possess [[antiinflammatory]] and anti-[[hyperalgesia|hyperalgesic]] effects at low doses, followed by [[ataxia]] and [[analgesic]] effects when the dose is increased.<ref>Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. ''Pain''. 2002 Apr;96(3):253-60. PMID 11972997</ref><ref>Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. ''Neuropharmacology''. 2005 Apr;48(5):658-72. PMID 15814101</ref> Selective CB₂ agonist drugs such as GW-405,833 are hoped to be particularly useful in the treatment of [[allodynia]] and [[neuropathic pain]] for which current treatment options are often inadequate.<ref>Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. ''European Journal of Neuroscience''. 2006 Mar;23(6):1530-8. {{DOI|10.1111/j.1460-9568.2006.04684.x}} PMID 16553616</ref><ref>Leichsenring A, Andriske M, Bäcker I, Stichel CC, Lübbert H. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. ''Naunyn Schmiedebergs Archives of Pharmacology''. 2009 Jan 18. PMID 19152053</ref>

==References==

<references/>

[[Category:Morpholines]]

[[Category:Organochlorides]]